{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:46:30Z","timestamp":1780523190042,"version":"3.54.1"},"reference-count":207,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2020,9,9]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>The endocannabinoid system participates in the regulation of CNS homeostasis and functions,\nincluding neurotransmission, cell signaling, inflammation and oxidative stress, as well as\nneuronal and glial cell proliferation, differentiation, migration and survival. Endocannabinoids are\nproduced by multiple cell types within the CNS and their main receptors, CB1 and CB2, are expressed\nin both neurons and glia. Signaling through these receptors is implicated in the modulation\nof neuronal and glial alterations in neuroinflammatory, neurodegenerative and psychiatric conditions,\nincluding Alzheimer\u2019s, Parkinson\u2019s and Huntington\u2019s disease, multiple sclerosis, amyotrophic\nlateral sclerosis, stroke, epilepsy, anxiety and depression. The therapeutic potential of endocannabinoid\nreceptors in neurological disease has been hindered by unwelcome side effects of current drugs\nused to target them; however, due to their extensive expression within the CNS and their involvement\nin physiological and pathological process in nervous tissue, they are attractive targets for drug\ndevelopment. The present review highlights the potential applications of the endocannabinoid system\nfor the prevention and treatment of neurologic and psychiatric disorders.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x18666200217140255","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T11:58:36Z","timestamp":1581940716000},"page":"769-787","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders"],"prefix":"10.2174","volume":"18","author":[{"given":"Jos\u00e9 Antonio","family":"Estrada","sequence":"first","affiliation":[{"name":"Neurochemistry Laboratory, Faculty of Medicine, Universidad Aut\u00f3noma del Estado de M\u00e9xico, Toluca, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraz\u00fa","family":"Contreras","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Faculty of Medicine, Universidad Aut\u00f3noma del Estado de M\u00e9xico, Toluca, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/372686a0","volume":"372","author":"Di Marzo V.","year":"1994","unstructured":"Di Marzo V.; Fontana A.; Cadas H.; Schinelli S.; Cimino G.; Schwartz J.C.; Piomelli D.; Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994,372(6507),686-691","journal-title":"Nature"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/42015","volume":"388","author":"Stella N.","year":"1997","unstructured":"Stella N.; Schweitzer P.; Piomelli D.; A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997,388(6644),773-778","journal-title":"Nature"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0006-2952(93)90486-G","volume":"46","author":"Deutsch D.G.","year":"1993","unstructured":"Deutsch D.G.; Chin S.A.; Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993,46(5),791-796","journal-title":"Biochem Pharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.chembiol.2007.11.006","volume":"14","author":"Blankman J.L.","year":"2007","unstructured":"Blankman J.L.; Simon G.M.; Cravatt B.F.; A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007,14(12),1347-1356","journal-title":"Chem Biol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1021\/cr0782067","volume":"108","author":"Ahn K.","year":"2008","unstructured":"Ahn K.; McKinney M.K.; Cravatt B.F.; Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008,108(5),1687-1707","journal-title":"Chem Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","volume":"87","author":"Herkenham M.","year":"1990","unstructured":"Herkenham M.; Lynn A.B.; Little M.D.; Johnson M.R.; Melvin L.S.; de Costa B.R.; Rice K.C.; Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990,87(5),1932-1936","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0006-8993(92)90428-C","volume":"575","author":"Jansen E.M.","year":"1992","unstructured":"Jansen E.M.; Haycock D.A.; Ward S.J.; Seybold V.S.; Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res 1992,575(1),93-102","journal-title":"Brain Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0306-4522(96)00428-9","volume":"77","author":"Glass M.","year":"1997","unstructured":"Glass M.; Dragunow M.; Faull R.L.; Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997,77(2),299-318","journal-title":"Neuroscience"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1046\/j.1460-9568.2003.02599.x","volume":"17","author":"Mato S.","year":"2003","unstructured":"Mato S.; Del Olmo E.; Pazos A.; Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci 2003,17(9),1747-1754","journal-title":"Eur J Neurosci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fncel.2016.00294","volume":"10","author":"Kendall D.A.","year":"2017","unstructured":"Kendall D.A.; Yudowski G.A.; Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease. Front Cell Neurosci 2017,10,294","journal-title":"Front Cell Neurosci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.plefa.2018.11.016","volume":"140","author":"Chanda D.","year":"2019","unstructured":"Chanda D.; Neumann D.; Glatz J.F.C.; The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target. Prostaglandins Leukot Essent Fatty Acids 2019,140,51-56","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030833","volume":"19","author":"Zou S.","year":"2018","unstructured":"Zou S.; Kumar U.; Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci 2018,19(3)","journal-title":"Int J Mol Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0896-6273(01)00246-X","volume":"29","author":"Kreitzer A.C.","year":"2001","unstructured":"Kreitzer A.C.; Regehr W.G.; Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 2001,29(3),717-727","journal-title":"Neuron"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0896-6273(01)00247-1","volume":"29","author":"Ohno-Shosaku T.","year":"2001","unstructured":"Ohno-Shosaku T.; Maejima T.; Kano M.; Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001,29(3),729-738","journal-title":"Neuron"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/35069076","volume":"410","author":"Wilson R.I.","year":"2001","unstructured":"Wilson R.I.; Nicoll R.A.; Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001,410(6828),588-592","journal-title":"Nature"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuron.2012.09.020","volume":"76","author":"Castillo P.E.","year":"2012","unstructured":"Castillo P.E.; Younts T.J.; Ch\u00e1vez A.E.; Hashimotodani Y.; Endocannabinoid signaling and synaptic function. Neuron 2012,76(1),70-81","journal-title":"Neuron"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41232-018-0086-5","volume":"38","author":"Tsuboi K.","year":"2018","unstructured":"Tsuboi K.; Uyama T.; Okamoto Y.; Ueda N.; Endocannabinoids and related N-acylethanolamines: biological activities and metabolism. Inflamm Regen 2018,38,28","journal-title":"Inflamm Regen"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.bjp.0705726","volume":"142","author":"Diana M.A.","year":"2004","unstructured":"Diana M.A.; Marty A.; Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol 2004,142(1),9-19","journal-title":"Br J Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/npp.2017.206","volume":"43","author":"Busquets-Garcia A.","year":"2018","unstructured":"Busquets-Garcia A.; Bains J.; Marsicano G.; CB1 Receptor Signaling in the Brain: Extracting Specificity from Ubiquity. Neuropsychopharmacology 2018,43(1),4-20","journal-title":"Neuropsychopharmacology"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.toxlet.2014.09.002","volume":"231","author":"Fi\u0161ar Z.","year":"2014","unstructured":"Fi\u0161ar Z.; Singh N.; Hroudov\u00e1 J.; Cannabinoid-induced changes in respiration of brain mitochondria. Toxicol Lett 2014,231(1),62-71","journal-title":"Toxicol Lett"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"10039","DOI":"10.1523\/JNEUROSCI.4112-14.2015","volume":"35","author":"Lee S.H.","year":"2015","unstructured":"Lee S.H.; Ledri M.; T\u00f3th B.; Marchionni I.; Henstridge C.M.; Dudok B.; Kenesei K.; Barna L.; Szab\u00f3 S.I.; Renkecz T.; Oberoi M.; Watanabe M.; Limoli C.L.; Horvai G.; Soltesz I.; Katona I.; Multiple forms of endocannabinoid and endovanilloid signaling regulate the tonic control of GABA release. J Neurosci 2015,35(27),10039-10057","journal-title":"J Neurosci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1073\/pnas.0901515106","volume":"106","author":"Kaczocha M.","year":"2009","unstructured":"Kaczocha M.; Glaser S.T.; Deutsch D.G.; Lennarz W.J.; Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci USA 2009,106(15),6375-6380","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054271","volume":"8","author":"Compagnucci C.","year":"2013","unstructured":"Compagnucci C.; Di Siena S.; Bustamante M.B.; Di Giacomo D.; Di Tommaso M.; Maccarrone M.; Grimaldi P.; Sette C.; Type-1 (CB1) cannabinoid receptor promotes neuronal differentiation and maturation of neural stem cells. PLoS One 2013,8(1)","journal-title":"PLoS One"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neuropharm.2017.06.017","volume":"124","author":"Araque A.","year":"2017","unstructured":"Araque A.; Castillo P.E.; Manzoni O.J.; Tonini R.; Synaptic functions of endocannabinoid signaling in health and disease. Neuropharmacology 2017,124,13-24","journal-title":"Neuropharmacology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.neuron.2016.03.034","volume":"90","author":"Stempel A.V.","year":"2016","unstructured":"Stempel A.V.; Stumpf A.; Zhang H.Y.; \u00d6zdo\u011fan T.; Pannasch U.; Theis A.K.; Otte D.M.; Wojtalla A.; R\u00e1cz I.; Ponomarenko A.; Xi Z.X.; Zimmer A.; Schmitz D.; Cannabinoid Type 2 receptors mediate a cell type-specific plasticity in the hippocampus. Neuron 2016,90(4),795-809","journal-title":"Neuron"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.neuropharm.2012.04.024","volume":"63","author":"Atwood B.K.","year":"2012","unstructured":"Atwood B.K.; Straiker A.; Mackie K.; CB cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. Neuropharmacology 2012,63(4),514-523","journal-title":"Neuropharmacology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fnins.2016.00406","volume":"10","author":"Navarro G.","year":"2016","unstructured":"Navarro G.; Morales P.; Rodr\u00edguez-Cueto C.; Fern\u00e1ndez-Ruiz J.; Jagerovic N.; Franco R.; Targeting cannabinoid CB2 receptors in the central nervous system. medicinal chemistry approaches with focus on neurodegenerative disorders. Front Neurosci 2016,10,406","journal-title":"Front Neurosci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.brainres.2005.11.035","volume":"1071","author":"Gong J.P.","year":"2006","unstructured":"Gong J.P.; Onaivi E.S.; Ishiguro H.; Liu Q.R.; Tagliaferro P.A.; Brusco A.; Uhl G.R.; Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006,1071(1),10-23","journal-title":"Brain Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/39807","volume":"389","author":"Caterina M.J.","year":"1997","unstructured":"Caterina M.J.; Schumacher M.A.; Tominaga M.; Rosen T.A.; Levine J.D.; Julius D.; The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997,389(6653),816-824","journal-title":"Nature"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/nn.2684","volume":"13","author":"Ch\u00e1vez A.E.","year":"2010","unstructured":"Ch\u00e1vez A.E.; Chiu C.Q.; Castillo P.E.; TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci 2010,13(12),1511-1518","journal-title":"Nat Neurosci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.conb.2013.12.006","volume":"26","author":"Younts T.J.","year":"2014","unstructured":"Younts T.J.; Castillo P.E.; Endogenous cannabinoid signaling at inhibitory interneurons. Curr Opin Neurobiol 2014,26,42-50","journal-title":"Curr Opin Neurobiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fnbeh.2016.00211","volume":"10","author":"Manduca A.","year":"2016","unstructured":"Manduca A.; Lassalle O.; Sepers M.; Campolongo P.; Cuomo V.; Marsicano G.; Kieffer B.; Vanderschuren L.J.; Trezza V.; Manzoni O.J.; interacting cannabinoid and opioid receptors in the nucleus accumbens core control adolescent social play. Front Behav Neurosci 2016,10,211","journal-title":"Front Behav Neurosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"20869","DOI":"10.1074\/jbc.M110813200","volume":"277","author":"Walter L.","year":"2002","unstructured":"Walter L.; Franklin A.; Witting A.; Moller T.; Stella N.; Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem 2002,277(23),20869-20876","journal-title":"J Biol Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/glia.10270","volume":"44","author":"Walter L.","year":"2003","unstructured":"Walter L.; Stella N.; Endothelin-1 increases 2-arachidonoyl glycerol (2-AG) production in astrocytes. Glia 2003,44(1),85-90","journal-title":"Glia"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.15252\/embr.201439668","volume":"16","author":"Gabrielli M.","year":"2015","unstructured":"Gabrielli M.; Battista N.; Riganti L.; Prada I.; Antonucci F.; Cantone L.; Matteoli M.; Maccarrone M.; Verderio C.; Active endocannabinoids are secreted on extracellular membrane vesicles. EMBO Rep 2015,16(2),213-220","journal-title":"EMBO Rep"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1073\/pnas.0306707101","volume":"101","author":"Witting A.","year":"2004","unstructured":"Witting A.; Walter L.; Wacker J.; M\u00f6ller T.; Stella N.; P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc Natl Acad Sci USA 2004,101(9),3214-3219","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/glia.22742","volume":"63","author":"Bernal-Chico A.","year":"2015","unstructured":"Bernal-Chico A.; Canedo M.; Manterola A.; Victoria S\u00e1nchez-G\u00f3mez M.; P\u00e9rez-Samart\u00edn A.; Rodr\u00edguez-Puertas R.; Matute C.; Mato S.; Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo. Glia 2015,63(1),163-176","journal-title":"Glia"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.neuron.2008.01.029","volume":"57","author":"Navarrete M.","year":"2008","unstructured":"Navarrete M.; Araque A.; Endocannabinoids mediate neuron-astrocyte communication. Neuron 2008,57(6),883-893","journal-title":"Neuron"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.neuron.2010.08.043","volume":"68","author":"Navarrete M.","year":"2010","unstructured":"Navarrete M.; Araque A.; Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 2010,68(1),113-126","journal-title":"Neuron"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1093\/cercor\/bhw172","volume":"26","author":"Andrade-Talavera Y.","year":"2016","unstructured":"Andrade-Talavera Y.; Duque-Feria P.; Paulsen O.; Rodr\u00edguez-Moreno A.; Presynaptic spike timing-dependent long-term depression in the mouse hippocampus. Cereb Cortex 2016,26(8),3637-3654","journal-title":"Cereb Cortex"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.cell.2012.01.037","volume":"148","author":"Han J.","year":"2012","unstructured":"Han J.; Kesner P.; Metna-Laurent M.; Duan T.; Xu L.; Georges F.; Koehl M.; Abrous D.N.; Mendizabal-Zubiaga J.; Grandes P.; Liu Q.; Bai G.; Wang W.; Xiong L.; Ren W.; Marsicano G.; Zhang X.; Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 2012,148(5),1039-1050","journal-title":"Cell"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.brainresbull.2018.06.012","volume":"142","author":"Gorzkiewicz A.","year":"2018","unstructured":"Gorzkiewicz A.; Szemraj J.; Brain endocannabinoid signaling exhibits remarkable complexity. Brain Res Bull 2018,142,33-46","journal-title":"Brain Res Bull"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.nbd.2005.11.004","volume":"22","author":"Panikashvili D.","year":"2006","unstructured":"Panikashvili D.; Shein N.A.; Mechoulam R.; Trembovler V.; Kohen R.; Alexandrovich A.; Shohami E.; The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 2006,22(2),257-264","journal-title":"Neurobiol Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1128\/MCB.00397-06","volume":"26","author":"Wettschureck N.","year":"2006","unstructured":"Wettschureck N.; van der Stelt M.; Tsubokawa H.; Krestel H.; Moers A.; Petrosino S.; Sch\u00fctz G.; Di Marzo V.; Offermanns S.; Forebrain-specific inactivation of Gq\/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation. Mol Cell Biol 2006,26(15),5888-5894","journal-title":"Mol Cell Biol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2967\/jnumed.110.077156","volume":"51","author":"Van Laere K.","year":"2010","unstructured":"Van Laere K.; Casteels C.; Dhollander I.; Goffin K.; Grachev I.; Bormans G.; Vandenberghe W.; Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med 2010,51(9),1413-1417","journal-title":"J Nucl Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/0306-4522(94)90511-8","volume":"63","author":"Westlake T.M.","year":"1994","unstructured":"Westlake T.M.; Howlett A.C.; Bonner T.I.; Matsuda L.A.; Herkenham M.; Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer\u2019s brains. Neuroscience 1994,63(3),637-652","journal-title":"Neuroscience"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1523\/JNEUROSCI.4628-11.2012","volume":"32","author":"Ramirez S.H.","year":"2012","unstructured":"Ramirez S.H.; Hask\u00f3 J.; Skuba A.; Fan S.; Dykstra H.; McCormick R.; Reichenbach N.; Krizbai I.; Mahadevan A.; Zhang M.; Tuma R.; Son Y.J.; Persidsky Y.; Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci 2012,32(12),4004-4016","journal-title":"J Neurosci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fnins.2017.00030","volume":"11","author":"Cassano T.","year":"2017","unstructured":"Cassano T.; Calcagnini S.; Pace L.; De Marco F.; Romano A.; Gaetani S.; Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target. Front Neurosci 2017,11,30","journal-title":"Front Neurosci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","volume":"29","author":"Giuffrida A.","year":"2004","unstructured":"Giuffrida A.; Leweke F.M.; Gerth C.W.; Schreiber D.; Koethe D.; Faulhaber J.; Klosterk\u00f6tter J.; Piomelli D.; Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004,29(11),2108-2114","journal-title":"Neuropsychopharmacology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1046\/j.1460-9568.2002.02192.x","volume":"16","author":"Haller J.","year":"2002","unstructured":"Haller J.; Bakos N.; Szirmay M.; Ledent C.; Freund T.F.; The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002,16(7),1395-1398","journal-title":"Eur J Neurosci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.nbd.2010.03.020","volume":"39","author":"Beyer C.E.","year":"2010","unstructured":"Beyer C.E.; Dwyer J.M.; Piesla M.J.; Platt B.J.; Shen R.; Rahman Z.; Chan K.; Manners M.T.; Samad T.A.; Kennedy J.D.; Bingham B.; Whiteside G.T.; Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 2010,39(2),148-155","journal-title":"Neurobiol Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1210\/en.2005-1649","volume":"148","author":"Cota D.","year":"2007","unstructured":"Cota D.; Steiner M.A.; Marsicano G.; Cervino C.; Herman J.P.; Gr\u00fcbler Y.; Stalla J.; Pasquali R.; Lutz B.; Stalla G.K.; Pagotto U.; Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 2007,148(4),1574-1581","journal-title":"Endocrinology"},{"key":"ref=53","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2013.0599","volume":"369","author":"Navarrete M.","year":"2014","unstructured":"Navarrete M.; D\u00edez A.; Araque A.; Astrocytes in endocannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2014,369(1654)","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"9406","DOI":"10.1073\/pnas.0914661107","volume":"107","author":"Hill M.N.","year":"2010","unstructured":"Hill M.N.; McLaughlin R.J.; Bingham B.; Shrestha L.; Lee T.T.; Gray J.M.; Hillard C.J.; Gorzalka B.B.; Viau V.; Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci USA 2010,107(20),9406-9411","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"52908","DOI":"10.1155\/2007\/52908","volume":"2007","author":"Viveros M.P.","year":"2007","unstructured":"Viveros M.P.; Marco E.M.; Llorente R.; L\u00f3pez-Gallardo M.; Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 2007,2007,52908","journal-title":"Neural Plast"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1016\/j.lfs.2004.06.006","volume":"75","author":"Barna I.","year":"2004","unstructured":"Barna I.; Zelena D.; Arszovszki A.C.; Ledent C.; The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 2004,75(24),2959-2970","journal-title":"Life Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1023\/A:1007074420772","volume":"20","author":"Abbott N.J.","year":"2000","unstructured":"Abbott N.J.; Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000,20(2),131-147","journal-title":"Cell Mol Neurobiol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"H1241","DOI":"10.1152\/ajpheart.2001.280.3.H1241","volume":"280","author":"Huber J.D.","year":"2001","unstructured":"Huber J.D.; Witt K.A.; Hom S.; Egleton R.D.; Mark K.S.; Davis T.P.; Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 2001,280(3),H1241-H1248","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1750-3639.1991.tb00646.x","volume":"1","author":"Hickey W.F.","year":"1991","unstructured":"Hickey W.F.; Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol 1991,1(2),97-105","journal-title":"Brain Pathol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/35068632","volume":"410","author":"Ek M.","year":"2001","unstructured":"Ek M.; Engblom D.; Saha S.; Blomqvist A.; Jakobsson P.J.; Ericsson-Dahlstrand A.; Inflammatory response: pathway across the blood-brain barrier. Nature 2001,410(6827),430-431","journal-title":"Nature"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1742-2094-8-102","volume":"8","author":"Mestre L.","year":"2011","unstructured":"Mestre L.; I\u00f1igo P.M.; Mecha M.; Correa F.G.; Hernang\u00f3mez-Herrero M.; Lor\u00eda F.; Docagne F.; Borrell J.; Guaza C.; Anandamide inhibits Theiler\u2019s virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors. J Neuroinflammation 2011,8,102","journal-title":"J Neuroinflammation"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0165-5728(95)00174-3","volume":"64","author":"Droogan A.G.","year":"1996","unstructured":"Droogan A.G.; McMillan S.A.; Douglas J.P.; Hawkins S.A.; Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1. J Neuroimmunol 1996,64(2),185-191","journal-title":"J Neuroimmunol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0165-5728(95)00023-U","volume":"59","author":"Matsuda M.","year":"1995","unstructured":"Matsuda M.; Tsukada N.; Miyagi K.; Yanagisawa N.; Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy. J Neuroimmunol 1995,59(1-2),35-40","journal-title":"J Neuroimmunol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000093243","volume":"22","author":"Rothoerl R.D.","year":"2006","unstructured":"Rothoerl R.D.; Schebesch K.M.; Kubitza M.; Woertgen C.; Brawanski A.; Pina A.L.; ICAM-1 and VCAM-1 expression following aneurysmal subarachnoid hemorrhage and their possible role in the pathophysiology of subsequent ischemic deficits. Cerebrovasc Dis 2006,22(2-3),143-149","journal-title":"Cerebrovasc Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jneuroim.2010.12.005","volume":"233","author":"Rossi B.","year":"2011","unstructured":"Rossi B.; Zenaro E.; Angiari S.; Ottoboni L.; Bach S.; Piccio L.; Pietronigro E.C.; Scarpini E.; Fusco M.; Leon A.; Constantin G.; Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism. J Neuroimmunol 2011,233(1-2),97-105","journal-title":"J Neuroimmunol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.ajpath.2013.07.033","volume":"183","author":"Rom S.","year":"2013","unstructured":"Rom S.; Zuluaga-Ramirez V.; Dykstra H.; Reichenbach N.L.; Pacher P.; Persidsky Y.; Selective activation of cannabinoid receptor 2 in leukocytes suppresses their engagement of the brain endothelium and protects the blood-brain barrier. Am J Pathol 2013,183(5),1548-1558","journal-title":"Am J Pathol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1160\/TH05-06-0413","volume":"95","author":"Maccarrone M.","year":"2006","unstructured":"Maccarrone M.; Fiori A.; Bari M.; Granata F.; Gasperi V.; De Stefano M.E.; Finazzi-Agr\u00f2 A.; Strom R.; Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thromb Haemost 2006,95(1),117-127","journal-title":"Thromb Haemost"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1111\/bph.13106","volume":"172","author":"Hind W.H.","year":"2015","unstructured":"Hind W.H.; Tufarelli C.; Neophytou M.; Anderson S.I.; England T.J.; O\u2019Sullivan S.E.; Endocannabinoids modulate human blood-brain barrier permeability in vitro. Br J Pharmacol 2015,172(12),3015-3027","journal-title":"Br J Pharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000110644","volume":"14","author":"Correa F.","year":"2007","unstructured":"Correa F.; Docagne F.; Mestre L.; Lor\u00eda F.; Hernang\u00f3mez M.; Borrell J.; Guaza C.; Cannabinoid system and neuroinflammation: implications for multiple sclerosis. Neuroimmunomodulation 2007,14(3-4),182-187","journal-title":"Neuroimmunomodulation"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","volume":"53","author":"Tang Y.","year":"2016","unstructured":"Tang Y.; Le W.; Differential roles of m1 and m2 microglia in neurodegenerative diseases. Mol Neurobiol 2016,53(2),1181-1194","journal-title":"Mol Neurobiol"},{"key":"ref=71","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/130639","volume":"2015","author":"Malek N.","year":"2015","unstructured":"Malek N.; Popiolek-Barczyk K.; Mika J.; Przewlocka B.; Starowicz K.; Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures. Neural Plast 2015,2015","journal-title":"Neural Plast"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fnmol.2018.00295","volume":"11","author":"Ativie F.","year":"2018","unstructured":"Ativie F.; Komorowska J.A.; Beins E.; Albayram \u00d6.; Zimmer T.; Zimmer A.; Tejera D.; Heneka M.; Bilkei-Gorzo A.; Cannabinoid 1 receptor signaling on hippocampal gabaergic neurons influences microglial activity. Front Mol Neurosci 2018,11,295","journal-title":"Front Mol Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1744-8069-5-25","volume":"5","author":"Romero-Sandoval E.A.","year":"2009","unstructured":"Romero-Sandoval E.A.; Horvath R.; Landry R.P.; DeLeo J.A.; Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. Mol Pain 2009,5,25","journal-title":"Mol Pain"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00213-015-4105-9","volume":"233","author":"Boorman E.","year":"2016","unstructured":"Boorman E.; Zajkowska Z.; Ahmed R.; Pariante C.M.; Zunszain P.A.; Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression? Psychopharmacology (Berl) 2016,233(9),1591-1604","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/glia.22366","volume":"60","author":"Hernang\u00f3mez M.","year":"2012","unstructured":"Hernang\u00f3mez M.; Mestre L.; Correa F.G.; Lor\u00eda F.; Mecha M.; I\u00f1igo P.M.; Docagne F.; Williams R.O.; Borrell J.; Guaza C.; CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia 2012,60(9),1437-1450","journal-title":"Glia"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1074\/jbc.M115.683615","volume":"291","author":"Grabner G.F.","year":"2016","unstructured":"Grabner G.F.; Eichmann T.O.; Wagner B.; Gao Y.; Farzi A.; Taschler U.; Radner F.P.; Schweiger M.; Lass A.; Holzer P.; Zinser E.; Tsch\u00f6p M.H.; Yi C.X.; Zimmermann R.; Deletion of monoglyceride lipase in astrocytes attenuates lipopolysaccharide-induced neuroinflammation. J Biol Chem 2016,291(2),913-923","journal-title":"J Biol Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s00018-012-1253-5","volume":"70","author":"Bisicchia E.","year":"2013","unstructured":"Bisicchia E.; Chiurchi\u00f9 V.; Viscomi M.T.; Latini L.; Fezza F.; Battistini L.; Maccarrone M.; Molinari M.; Activation of type-2 cannabinoid receptor inhibits neuroprotective and antiinflammatory actions of glucocorticoid receptor \u03b1: when one is better than two. Cell Mol Life Sci 2013,70(12),2191-2204","journal-title":"Cell Mol Life Sci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0925-4439(98)00042-8","volume":"1407","author":"Berrendero F.","year":"1998","unstructured":"Berrendero F.; Romero J.; Garc\u00eda-Gil L.; Suarez I.; De la Cruz P.; Ramos J.A.; Fern\u00e1ndez-Ruiz J.J.; Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. Biochim Biophys Acta 1998,1407(3),205-214","journal-title":"Biochim Biophys Acta"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1471-2202-13-87","volume":"13","author":"Long L.E.","year":"2012","unstructured":"Long L.E.; Lind J.; Webster M.; Weickert C.S.; Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex. BMC Neurosci 2012,13,87","journal-title":"BMC Neurosci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0024-3205(01)01516-8","volume":"70","author":"Wenger T.","year":"2002","unstructured":"Wenger T.; Gerendai I.; Fezza F.; Gonz\u00e1lez S.; Bisogno T.; Fernandez-Ruiz J.; Di Marzo V.; The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. Life Sci 2002,70(12),1407-1414","journal-title":"Life Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrn3876","volume":"16","author":"Di Marzo V.","year":"2015","unstructured":"Di Marzo V.; Stella N.; Zimmer A.; Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci 2015,16(1),30-42","journal-title":"Nat Rev Neurosci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"11256","DOI":"10.1073\/pnas.1016442108","volume":"108","author":"Albayram O.","year":"2011","unstructured":"Albayram O.; Alferink J.; Pitsch J.; Piyanova A.; Neitzert K.; Poppensieker K.; Mauer D.; Michel K.; Legler A.; Becker A.; Monory K.; Lutz B.; Zimmer A.; Bilkei-Gorzo A.; Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging. Proc Natl Acad Sci USA 2011,108(27),11256-11261","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202566","volume":"13","author":"Bilkei-Gorzo A.","year":"2018","unstructured":"Bilkei-Gorzo A.; Albayram O.; Ativie F.; Chasan S.; Zimmer T.; Bach K.; Zimmer A.; Cannabinoid 1 receptor signaling on GABAergic neurons influences astrocytes in the ageing brain. PLoS One 2018,13(8)","journal-title":"PLoS One"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/glia.20983","volume":"58","author":"Stella N.","year":"2010","unstructured":"Stella N.; Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010,58(9),1017-1030","journal-title":"Glia"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.neuroscience.2013.09.005","volume":"254","author":"Ribeiro R.","year":"2013","unstructured":"Ribeiro R.; Yu F.; Wen J.; Vana A.; Zhang Y.; Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis. Neuroscience 2013,254,427-442","journal-title":"Neuroscience"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/brain\/awp239","volume":"132","author":"Palazuelos J.","year":"2009","unstructured":"Palazuelos J.; Aguado T.; Pazos M.R.; Julien B.; Carrasco C.; Resel E.; Sagredo O.; Benito C.; Romero J.; Azcoitia I.; Fern\u00e1ndez-Ruiz J.; Guzm\u00e1n M.; Galve-Roperh I.; Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity. Brain 2009,132(Pt 11),3152-3164","journal-title":"Brain"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","volume":"110","author":"Hardy J.","year":"2009","unstructured":"Hardy J.; The amyloid hypothesis for Alzheimer\u2019s disease: a critical reappraisal. J Neurochem 2009,110(4),1129-1134","journal-title":"J Neurochem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijdevneu.2005.11.014","volume":"24","author":"Sastre M.","year":"2006","unstructured":"Sastre M.; Klockgether T.; Heneka M.T.; Contribution of inflammatory processes to Alzheimer\u2019s disease: molecular mechanisms. Int J Dev Neurosci 2006,24(2-3),167-176","journal-title":"Int J Dev Neurosci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nbd.2004.12.013","volume":"18","author":"White J.A.","year":"2005","unstructured":"White J.A.; Manelli A.M.; Holmberg K.H.; Van Eldik L.J.; Ladu M.J.; Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 2005,18(3),459-465","journal-title":"Neurobiol Dis"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1088208","volume":"302","author":"Marsicano G.","year":"2003","unstructured":"Marsicano G.; Goodenough S.; Monory K.; Hermann H.; Eder M.; Cannich A.; Azad S.C.; Cascio M.G.; Guti\u00e9rrez S.O.; van der Stelt M.; L\u00f3pez-Rodriguez M.L.; Casanova E.; Sch\u00fctz G.; Zieglg\u00e4nsberger W.; Di Marzo V.; Behl C.; Lutz B.; CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003,302(5642),84-88","journal-title":"Science"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/brain\/awr046","volume":"134","author":"Mulder J.","year":"2011","unstructured":"Mulder J.; Zilberter M.; Pasquar\u00e9 S.J.; Alp\u00e1r A.; Schulte G.; Ferreira S.G.; K\u00f6falvi A.; Mart\u00edn-Moreno A.M.; Keimpema E.; Tanila H.; Watanabe M.; Mackie K.; Hortob\u00e1gyi T.; de Ceballos M.L.; Harkany T.; Molecular reorganization of endocannabinoid signalling in Alzheimer\u2019s disease. Brain 2011,134(Pt 4),1041-1060","journal-title":"Brain"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.neurobiolaging.2011.03.012","volume":"33","author":"Jung K.M.","year":"2012","unstructured":"Jung K.M.; Astarita G.; Yasar S.; Vasilevko V.; Cribbs D.H.; Head E.; Cotman C.W.; Piomelli D.; An amyloid \u03b242-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer\u2019s disease. Neurobiol Aging 2012,33(8),1522-1532","journal-title":"Neurobiol Aging"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","volume":"23","author":"Benito C.","year":"2003","unstructured":"Benito C.; N\u00fa\u00f1ez E.; Tol\u00f3n R.M.; Carrier E.J.; R\u00e1bano A.; Hillard C.J.; Romero J.; Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer\u2019s disease brains. J Neurosci 2003,23(35),11136-11141","journal-title":"J Neurosci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","volume":"25","author":"Ram\u00edrez B.G.","year":"2005","unstructured":"Ram\u00edrez B.G.; Bl\u00e1zquez C.; G\u00f3mez del Pulgar T.; Guzm\u00e1n M.; de Ceballos M.L.; Prevention of Alzheimer\u2019s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005,25(8),1904-1913","journal-title":"J Neurosci"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.euroneuro.2013.10.002","volume":"24","author":"Ahmad R.","year":"2014","unstructured":"Ahmad R.; Goffin K.; Van den Stock J.; De Winter F.L.; Cleeren E.; Bormans G.; Tournoy J.; Persoons P.; Van Laere K.; Vandenbulcke M.; In vivo type 1 cannabinoid receptor availability in Alzheimer\u2019s disease. Eur Neuropsychopharmacol 2014,24(2),242-250","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.neurobiolaging.2012.06.005","volume":"34","author":"Solas M.","year":"2013","unstructured":"Solas M.; Francis P.T.; Franco R.; Ram\u00edrez M.J.; CB2 receptor and amyloid pathology in frontal cortex of Alzheimer\u2019s disease patients. Neurobiol Aging 2013,34(3),805-808","journal-title":"Neurobiol Aging"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"16012","DOI":"10.1038\/npjamd.2016.12","volume":"2","author":"Currais A.","year":"2016","unstructured":"Currais A.; Quehenberger O.M.; Armando A.; Daugherty D.; Maher P.; Schubert D.; Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. NPJ Aging Mech Dis 2016,2,16012","journal-title":"NPJ Aging Mech Dis"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1742-2094-2-29","volume":"2","author":"Ehrhart J.","year":"2005","unstructured":"Ehrhart J.; Obregon D.; Mori T.; Hou H.; Sun N.; Bai Y.; Klein T.; Fernandez F.; Tan J.; Shytle R.D.; Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005,2,29","journal-title":"J Neuroinflammation"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10571-013-9984-x","volume":"34","author":"Janefjord E.","year":"2014","unstructured":"Janefjord E.; M\u00e5\u00e5g J.L.; Harvey B.S.; Smid S.D.; Cannabinoid effects on \u03b2 amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell Mol Neurobiol 2014,34(1),31-42","journal-title":"Cell Mol Neurobiol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.neuro.2011.12.015","volume":"33","author":"Harvey B.S.","year":"2012","unstructured":"Harvey B.S.; Ohlsson K.S.; M\u00e5\u00e5g J.L.; Musgrave I.F.; Smid S.D.; Contrasting protective effects of cannabinoids against oxidative stress and amyloid-\u03b2 evoked neurotoxicity in vitro. Neurotoxicology 2012,33(1),138-146","journal-title":"Neurotoxicology"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1007\/s00018-006-6037-3","volume":"63","author":"van der Stelt M.","year":"2006","unstructured":"van der Stelt M.; Mazzola C.; Esposito G.; Matias I.; Petrosino S.; De Filippis D.; Micale V.; Steardo L.; Drago F.; Iuvone T.; Di Marzo V.; Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 2006,63(12),1410-1424","journal-title":"Cell Mol Life Sci"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"34709","DOI":"10.1074\/jbc.M112.350678","volume":"287","author":"Tanveer R.","year":"2012","unstructured":"Tanveer R.; Gowran A.; Noonan J.; Keating S.E.; Bowie A.G.; Campbell V.A.; The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-\u03b2 and in the cortex of aged rats. J Biol Chem 2012,287(41),34709-34721","journal-title":"J Biol Chem"},{"key":"ref=103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028668","volume":"6","author":"Esposito G.","year":"2011","unstructured":"Esposito G.; Scuderi C.; Valenza M.; Togna G.I.; Latina V.; De Filippis D.; Cipriano M.; Carrat\u00f9 M.R.; Iuvone T.; Steardo L.; Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement. PLoS One 2011,6(12)","journal-title":"PLoS One"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-9-8","volume":"9","author":"Mart\u00edn-Moreno A.M.","year":"2012","unstructured":"Mart\u00edn-Moreno A.M.; Brera B.; Spuch C.; Carro E.; Garc\u00eda-Garc\u00eda L.; Delgado M.; Pozo M.A.; Innamorato N.G.; Cuadrado A.; de Ceballos M.L.; Prolonged oral cannabinoid administration prevents neuroinflammation, lowers \u03b2-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 2012,9,8","journal-title":"J Neuroinflammation"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.mcn.2013.06.004","volume":"56","author":"Bachmeier C.","year":"2013","unstructured":"Bachmeier C.; Beaulieu-Abdelahad D.; Mullan M.; Paris D.; Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier. Mol Cell Neurosci 2013,56,255-262","journal-title":"Mol Cell Neurosci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3233\/JAD-130137","volume":"35","author":"Aso E.","year":"2013","unstructured":"Aso E.; Juv\u00e9s S.; Maldonado R.; Ferrer I.; CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A\u03b2PP\/PS1 mice. J Alzheimers Dis 2013,35(4),847-858","journal-title":"J Alzheimers Dis"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.neulet.2006.06.012","volume":"404","author":"Esposito G.","year":"2006","unstructured":"Esposito G.; De Filippis D.; Steardo L.; Scuderi C.; Savani C.; Cuomo V.; Iuvone T.; CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci Lett 2006,404(3),342-346","journal-title":"Neurosci Lett"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3233\/JAD-2012-111862","volume":"30","author":"Aso E.","year":"2012","unstructured":"Aso E.; Palomer E.; Juv\u00e9s S.; Maldonado R.; Mu\u00f1oz F.J.; Ferrer I.; CB1 agonist ACEA protects neurons and reduces the cognitive impairment of A\u03b2PP\/PS1 mice. J Alzheimers Dis 2012,30(2),439-459","journal-title":"J Alzheimers Dis"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JCP.0b013e31820e861c","volume":"31","author":"Walther S.","year":"2011","unstructured":"Walther S.; Sch\u00fcpbach B.; Seifritz E.; Homan P.; Strik W.; Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol 2011,31(2),256-258","journal-title":"J Clin Psychopharmacol"},{"key":"ref=110","volume":"2","author":"Krishnan S.","year":"2009","unstructured":"Krishnan S.; Cairns R.; Howard R.; Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 2009,2(2)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","volume":"63","author":"Carroll C.B.","year":"2004","unstructured":"Carroll C.B.; Bain P.G.; Teare L.; Liu X.; Joint C.; Wroath C.; Parkin S.G.; Fox P.; Wright D.; Hobart J.; Zajicek J.P.; Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004,63(7),1245-1250","journal-title":"Neurology"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/1073858414524632","volume":"21","author":"Xu J.Y.","year":"2015","unstructured":"Xu J.Y.; Chen C.; Endocannabinoids in synaptic plasticity and neuroprotection. Neuroscientist 2015,21(2),152-168","journal-title":"Neuroscientist"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/mds.23014","volume":"25","author":"Pisani V.","year":"2010","unstructured":"Pisani V.; Moschella V.; Bari M.; Fezza F.; Galati S.; Bernardi G.; Stanzione P.; Pisani A.; Maccarrone M.; Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson\u2019s disease patients. Mov Disord 2010,25(7),920-924","journal-title":"Mov Disord"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.brainres.2004.02.016","volume":"1007","author":"de Lago E.","year":"2004","unstructured":"de Lago E.; de Miguel R.; Lastres-Becker I.; Ramos J.A.; Fern\u00e1ndez-Ruiz J.; Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res 2004,1007(1-2),152-159","journal-title":"Brain Res"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/0091-3057(93)90230-Q","volume":"46","author":"Crawley J.N.","year":"1993","unstructured":"Crawley J.N.; Corwin R.L.; Robinson J.K.; Felder C.C.; Devane W.A.; Axelrod J.; Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 1993,46(4),967-972","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1212\/01.wnl.0000267407.79757.75","volume":"69","author":"Benarroch E.","year":"2007","unstructured":"Benarroch E.; Endocannabinoids in basal ganglia circuits: implications for Parkinson disease. Neurology 2007,69(3),306-309","journal-title":"Neurology"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1460-9568.2008.06551.x","volume":"29","author":"Adermark L.","year":"2009","unstructured":"Adermark L.; Talani G.; Lovinger D.M.; Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur J Neurosci 2009,29(1),32-41","journal-title":"Eur J Neurosci"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1046\/j.0953-816x.2001.01812.x","volume":"14","author":"Lastres-Becker I.","year":"2001","unstructured":"Lastres-Becker I.; Cebeira M.; de Ceballos M.L.; Zeng B.Y.; Jenner P.; Ramos J.A.; Fern\u00e1ndez-Ruiz J.J.; Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson\u2019s syndrome and of MPTP-treated marmosets. Eur J Neurosci 2001,14(11),1827-1832","journal-title":"Eur J Neurosci"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1096\/fj.04-3010fje","volume":"19","author":"van der Stelt M.","year":"2005","unstructured":"van der Stelt M.; Fox S.H.; Hill M.; Crossman A.R.; Petrosino S.; Di Marzo V.; Brotchie J.M.; A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson\u2019s disease. FASEB J 2005,19(9),1140-1142","journal-title":"FASEB J"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"620.e1","DOI":"10.1016\/j.neurobiolaging.2011.02.009","volume":"33","author":"Van Laere K.","year":"2012","unstructured":"Van Laere K.; Casteels C.; Lunskens S.; Goffin K.; Grachev I.D.; Bormans G.; Vandenberghe W.; Regional changes in type 1 cannabinoid receptor availability in Parkinson\u2019s disease in vivo. Neurobiol Aging 2012,33(3),620.e1-620.e8","journal-title":"Neurobiol Aging"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/syn.20807","volume":"64","author":"Lane D.A.","year":"2010","unstructured":"Lane D.A.; Chan J.; Lupica C.R.; Pickel V.M.; Cannabinoid-1 receptor gene deletion has a compartment-specific affect on the dendritic and axonal availability of \u03bc-opioid receptors and on dopamine axons in the mouse nucleus accumbens. Synapse 2010,64(12),886-897","journal-title":"Synapse"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.neurobiolaging.2009.03.017","volume":"32","author":"P\u00e9rez-Rial S.","year":"2011","unstructured":"P\u00e9rez-Rial S.; Garc\u00eda-Guti\u00e9rrez M.S.; Molina J.A.; P\u00e9rez-Nievas B.G.; Ledent C.; Leiva C.; Leza J.C.; Manzanares J.; Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. Neurobiol Aging 2011,32(4),631-645","journal-title":"Neurobiol Aging"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","volume":"64","author":"G\u00f3mez-G\u00e1lvez Y.","year":"2016","unstructured":"G\u00f3mez-G\u00e1lvez Y.; Palomo-Garo C.; Fern\u00e1ndez-Ruiz J.; Garc\u00eda C.; Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 2016,64,200-208","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1111\/j.1460-9568.2009.06764.x","volume":"29","author":"Price D.A.","year":"2009","unstructured":"Price D.A.; Martinez A.A.; Seillier A.; Koek W.; Acosta Y.; Fernandez E.; Strong R.; Lutz B.; Marsicano G.; Roberts J.L.; Giuffrida A.; WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Eur J Neurosci 2009,29(11),2177-2186","journal-title":"Eur J Neurosci"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","volume":"163","author":"Garc\u00eda C.","year":"2011","unstructured":"Garc\u00eda C.; Palomo-Garo C.; Garc\u00eda-Arencibia M.; Ramos J.; Pertwee R.; Fern\u00e1ndez-Ruiz J.; Symptom-relieving and neuroprotective effects of the phytocannabinoid \u0394-THCV in animal models of Parkinson\u2019s disease. Br J Pharmacol 2011,163(7),1495-1506","journal-title":"Br J Pharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"421.e1","DOI":"10.1016\/j.neurobiolaging.2010.09.012","volume":"33","author":"Ternianov A.","year":"2012","unstructured":"Ternianov A.; P\u00e9rez-Ortiz J.M.; Solesio M.E.; Garc\u00eda-Guti\u00e9rrez M.S.; Ortega-\u00c1lvaro A.; Navarrete F.; Leiva C.; Galindo M.F.; Manzanares J.; Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine. Neurobiol Aging 2012,33(2),421.e1-421.e16","journal-title":"Neurobiol Aging"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","volume":"19","author":"Lastres-Becker I.","year":"2005","unstructured":"Lastres-Becker I.; Molina-Holgado F.; Ramos J.A.; Mechoulam R.; Fern\u00e1ndez-Ruiz J.; Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson\u2019s disease. Neurobiol Dis 2005,19(1-2),96-107","journal-title":"Neurobiol Dis"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/mds.20111","volume":"19","author":"Venderov\u00e1 K.","year":"2004","unstructured":"Venderov\u00e1 K.; R\u016fzicka E.; Vor\u00edsek V.; Visnovsk\u00fd P.; Survey on cannabis use in Parkinson\u2019s disease: subjective improvement of motor symptoms. Mov Disord 2004,19(9),1102-1106","journal-title":"Mov Disord"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ctim.2017.07.002","volume":"33","author":"Kindred J.H.","year":"2017","unstructured":"Kindred J.H.; Li K.; Ketelhut N.B.; Proessl F.; Fling B.W.; Honce J.M.; Shaffer W.R.; Rudroff T.; Cannabis use in people with Parkinson\u2019s disease and Multiple Sclerosis: A web-based investigation. Complement Ther Med 2017,33,99-104","journal-title":"Complement Ther Med"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","volume":"57","author":"Sieradzan K.A.","year":"2001","unstructured":"Sieradzan K.A.; Fox S.H.; Hill M.; Dick J.P.; Crossman A.R.; Brotchie J.M.; Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study. Neurology 2001,57(11),2108-2111","journal-title":"Neurology"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","volume":"27","author":"Mesnage V.","year":"2004","unstructured":"Mesnage V.; Houeto J.L.; Bonnet A.M.; Clavier I.; Arnulf I.; Cattelin F.; Le Fur G.; Damier P.; Welter M.L.; Agid Y.; Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol 2004,27(3),108-110","journal-title":"Clin Neuropharmacol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.neuropharm.2012.01.030","volume":"62","author":"de Lago E.","year":"2012","unstructured":"de Lago E.; Moreno-Martet M.; Cabranes A.; Ramos J.A.; Fern\u00e1ndez-Ruiz J.; Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 2012,62(7),2299-2308","journal-title":"Neuropharmacology"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s11481-013-9493-1","volume":"8","author":"Kozela E.","year":"2013","unstructured":"Kozela E.; Juknat A.; Kaushansky N.; Rimmerman N.; Ben-Nun A.; Vogel Z.; Cannabinoids decrease the th17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol 2013,8(5),1265-1276","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3109\/08830185.2014.921165","volume":"34","author":"Sido J.M.","year":"2015","unstructured":"Sido J.M.; Nagarkatti P.S.; Nagarkatti M.; Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease. Int Rev Immunol 2015,34(5),403-414","journal-title":"Int Rev Immunol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.nbd.2009.09.020","volume":"37","author":"Lor\u00eda F.","year":"2010","unstructured":"Lor\u00eda F.; Petrosino S.; Hernang\u00f3mez M.; Mestre L.; Spagnolo A.; Correa F.; Di Marzo V.; Docagne F.; Guaza C.; An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis 2010,37(1),166-176","journal-title":"Neurobiol Dis"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.brainres.2011.03.020","volume":"1390","author":"Lourbopoulos A.","year":"2011","unstructured":"Lourbopoulos A.; Grigoriadis N.; Lagoudaki R.; Touloumi O.; Polyzoidou E.; Mavromatis I.; Tascos N.; Breuer A.; Ovadia H.; Karussis D.; Shohami E.; Mechoulam R.; Simeonidou C.; Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res 2011,1390,126-141","journal-title":"Brain Res"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3389\/fimmu.2017.00753","volume":"8","author":"Arellano G.","year":"2017","unstructured":"Arellano G.; Acu\u00f1a E.; Reyes L.I.; Ottum P.A.; De Sarno P.; Villarroel L.; Ciampi E.; Uribe-San Mart\u00edn R.; C\u00e1rcamo C.; Naves R.; Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes. Front Immunol 2017,8,753","journal-title":"Front Immunol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/j.1476-5381.2011.01379.x","volume":"163","author":"Kozela E.","year":"2011","unstructured":"Kozela E.; Lev N.; Kaushansky N.; Eilam R.; Rimmerman N.; Levy R.; Ben-Nun A.; Juknat A.; Vogel Z.; Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL\/6 mice. Br J Pharmacol 2011,163(7),1507-1519","journal-title":"Br J Pharmacol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.bbi.2018.12.013","volume":"77","author":"Mecha M.","year":"2019","unstructured":"Mecha M.; Yanguas-Cas\u00e1s N.; Feli\u00fa A.; Mestre L.; Carrillo-Salinas F.; Azcoitia I.; Yong V.W.; Guaza C.; The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia. Brain Behav Immun 2019,77,110-126","journal-title":"Brain Behav Immun"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm1561","volume":"13","author":"Maresz K.","year":"2007","unstructured":"Maresz K.; Pryce G.; Ponomarev E.D.; Marsicano G.; Croxford J.L.; Shriver L.P.; Ledent C.; Cheng X.; Carrier E.J.; Mann M.K.; Giovannoni G.; Pertwee R.G.; Yamamura T.; Buckley N.E.; Hillard C.J.; Lutz B.; Baker D.; Dittel B.N.; Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007,13(4),492-497","journal-title":"Nat Med"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2013.11.002","volume":"287","author":"Kong W.","year":"2014","unstructured":"Kong W.; Li H.; Tuma R.F.; Ganea D.; Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS. Cell Immunol 2014,287(1),1-17","journal-title":"Cell Immunol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","volume":"362","author":"Zajicek J.","year":"2003","unstructured":"Zajicek J.; Fox P.; Sanders H.; Wright D.; Vickery J.; Nunn A.; Thompson A.; Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003,362(9395),1517-1526","journal-title":"Lancet"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nrn4036","volume":"16","author":"Lutz B.","year":"2015","unstructured":"Lutz B.; Marsicano G.; Maldonado R.; Hillard C.J.; The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci 2015,16(12),705-718","journal-title":"Nat Rev Neurosci"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.neuropharm.2007.06.024","volume":"54","author":"Rubino T.","year":"2008","unstructured":"Rubino T.; Guidali C.; Vigano D.; Realini N.; Valenti M.; Massi P.; Parolaro D.; CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 2008,54(1),151-160","journal-title":"Neuropharmacology"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.celrep.2014.11.001","volume":"9","author":"Shonesy B.C.","year":"2014","unstructured":"Shonesy B.C.; Bluett R.J.; Ramikie T.S.; B\u00e1ldi R.; Hermanson D.J.; Kingsley P.J.; Marnett L.J.; Winder D.G.; Colbran R.J.; Patel S.; Genetic disruption of 2-arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation. Cell Rep 2014,9(5),1644-1653","journal-title":"Cell Rep"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1517\/17460441.2014.966680","volume":"10","author":"Wyrofsky R.","year":"2015","unstructured":"Wyrofsky R.; McGonigle P.; Van Bockstaele E.J.; Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease. Expert Opin Drug Discov 2015,10(1),17-36","journal-title":"Expert Opin Drug Discov"},{"key":"ref=147","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/276902","volume":"2012","author":"Tao R.","year":"2012","unstructured":"Tao R.; Ma Z.; Neural circuit in the dorsal raphe nucleus responsible for cannabinoid-mediated increases in 5-HT efflux in the nucleus accumbens of the rat brain. ISRN Pharmacol 2012,2012","journal-title":"ISRN Pharmacol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/archgenpsychiatry.2011.5","volume":"68","author":"Large M.","year":"2011","unstructured":"Large M.; Sharma S.; Compton M.T.; Slade T.; Nielssen O.; Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 2011,68(6),555-561","journal-title":"Arch Gen Psychiatry"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","volume":"66","author":"Fusar-Poli P.","year":"2009","unstructured":"Fusar-Poli P.; Crippa J.A.; Bhattacharyya S.; Borgwardt S.J.; Allen P.; Martin-Santos R.; Seal M.; Surguladze S.A.; O\u2019Carrol C.; Atakan Z.; Zuardi A.W.; McGuire P.K.; Distinct effects of delta9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009,66(1),95-105","journal-title":"Arch Gen Psychiatry"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1038\/npp.2009.114","volume":"34","author":"Hill M.N.","year":"2009","unstructured":"Hill M.N.; McLaughlin R.J.; Morrish A.C.; Viau V.; Floresco S.B.; Hillard C.J.; Gorzalka B.B.; Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 2009,34(13),2733-2745","journal-title":"Neuropsychopharmacology"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1210\/en.2005-0610","volume":"146","author":"Di S.","year":"2005","unstructured":"Di S.; Malcher-Lopes R.; Marcheselli V.L.; Bazan N.G.; Tasker J.G.; Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and \u03b3-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 2005,146(10),4292-4301","journal-title":"Endocrinology"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/mp.2012.90","volume":"18","author":"Hill M.N.","year":"2013","unstructured":"Hill M.N.; Kumar S.A.; Filipski S.B.; Iverson M.; Stuhr K.L.; Keith J.M.; Cravatt B.F.; Hillard C.J.; Chattarji S.; McEwen B.S.; Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry 2013,18(10),1125-1135","journal-title":"Mol Psychiatry"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"9904","DOI":"10.1073\/pnas.1525066113","volume":"113","author":"Busquets-Garcia A.","year":"2016","unstructured":"Busquets-Garcia A.; Gomis-Gonz\u00e1lez M.; Srivastava R.K.; Cutando L.; Ortega-Alvaro A.; Ruehle S.; Remmers F.; Bindila L.; Bellocchio L.; Marsicano G.; Lutz B.; Maldonado R.; Ozaita A.; Peripheral and central CB1 cannabinoid receptors control stress-induced impairment of memory consolidation. Proc Natl Acad Sci USA 2016,113(35),9904-9909","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=154","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23081836","volume":"23","author":"Ishiguro H.","year":"2018","unstructured":"Ishiguro H.; Horiuchi Y.; Tabata K.; Liu Q.R.; Arinami T.; Onaivi E.S.; Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders. Molecules 2018,23(8)","journal-title":"Molecules"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","volume":"71","author":"Howren M.B.","year":"2009","unstructured":"Howren M.B.; Lamkin D.M.; Suls J.; Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009,71(2),171-186","journal-title":"Psychosom Med"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Dowlati Y.","year":"2010","unstructured":"Dowlati Y.; Herrmann N.; Swardfager W.; Liu H.; Sham L.; Reim E.K.; Lanct\u00f4t K.L.; A meta-analysis of cytokines in major depression. Biol Psychiatry 2010,67(5),446-457","journal-title":"Biol Psychiatry"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/01.mcg.0000210099.36500.fe","volume":"40","author":"Asnis G.M.","year":"2006","unstructured":"Asnis G.M.; De La Garza R.; II Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006,40(4),322-335","journal-title":"J Clin Gastroenterol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","volume":"367","author":"Tyring S.","year":"2006","unstructured":"Tyring S.; Gottlieb A.; Papp K.; Gordon K.; Leonardi C.; Wang A.; Lalla D.; Woolley M.; Jahreis A.; Zitnik R.; Cella D.; Krishnan R.; Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006,367(9504),29-35","journal-title":"Lancet"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/cercor\/bhr229","volume":"22","author":"Hinwood M.","year":"2012","unstructured":"Hinwood M.; Morandini J.; Day T.A.; Walker F.R.; Evidence that microglia mediate the neurobiological effects of chronic psychological stress on the medial prefrontal cortex. Cereb Cortex 2012,22(6),1442-1454","journal-title":"Cereb Cortex"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neuroscience.2015.02.028","volume":"294","author":"Su F.","year":"2015","unstructured":"Su F.; Yi H.; Xu L.; Zhang Z.; Fluoxetine and S-citalopram inhibit M1 activation and promote M2 activation of microglia in vitro. Neuroscience 2015,294,60-68","journal-title":"Neuroscience"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","volume":"23","author":"Moreira F.A.","year":"2009","unstructured":"Moreira F.A.; Grieb M.; Lutz B.; Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 2009,23(1),133-144","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/j.bja.2019.02.019","volume":"123","author":"Habib A.M.","year":"2019","unstructured":"Habib A.M.; Okorokov A.L.; Hill M.N.; Bras J.T.; Lee M.C.; Li S.; Gossage S.J.; van Drimmelen M.; Morena M.; Houlden H.; Ramirez J.D.; Bennett D.L.H.; Srivastava D.; Cox J.J.; Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. Br J Anaesth 2019,123(2),e249-e253","journal-title":"Br J Anaesth"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.1073\/pnas.161191698","volume":"98","author":"Cravatt B.F.","year":"2001","unstructured":"Cravatt B.F.; Demarest K.; Patricelli M.P.; Bracey M.H.; Giang D.K.; Martin B.R.; Lichtman A.H.; Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001,98(16),9371-9376","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.pain.2004.01.022","volume":"109","author":"Lichtman A.H.","year":"2004","unstructured":"Lichtman A.H.; Shelton C.C.; Advani T.; Cravatt B.F.; Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 2004,109(3),319-327","journal-title":"Pain"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.pain.2012.04.020","volume":"153","author":"Huggins J.P.","year":"2012","unstructured":"Huggins J.P.; Smart T.S.; Langman S.; Taylor L.; Young T.; An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012,153(9),1837-1846","journal-title":"Pain"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1056\/NEJMoa1604221","volume":"375","author":"Kerbrat A.","year":"2016","unstructured":"Kerbrat A.; Ferr\u00e9 J.C.; Fillatre P.; Ronzi\u00e8re T.; Vannier S.; Carsin-Nicol B.; Lavou\u00e9 S.; V\u00e9rin M.; Gauvrit J.Y.; Le Tulzo Y.; Edan G.; Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. N Engl J Med 2016,375(18),1717-1725","journal-title":"N Engl J Med"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/28393","volume":"394","author":"Calignano A.","year":"1998","unstructured":"Calignano A.; La Rana G.; Giuffrida A.; Piomelli D.; Control of pain initiation by endogenous cannabinoids. Nature 1998,394(6690),277-281","journal-title":"Nature"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/sj.bjp.0706990","volume":"150","author":"Guindon J.","year":"2007","unstructured":"Guindon J.; Desroches J.; Beaulieu P.; The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 2007,150(6),693-701","journal-title":"Br J Pharmacol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1021\/jm070317a","volume":"50","author":"Dziadulewicz E.K.","year":"2007","unstructured":"Dziadulewicz E.K.; Bevan S.J.; Brain C.T.; Coote P.R.; Culshaw A.J.; Davis A.J.; Edwards L.J.; Fisher A.J.; Fox A.J.; Gentry C.; Groarke A.; Hart T.W.; Huber W.; James I.F.; Kesingland A.; La Vecchia L.; Loong Y.; Lyothier I.; McNair K.; O\u2019Farrell C.; Peacock M.; Portmann R.; Schopfer U.; Yaqoob M.; Zadrobilek J.; Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1\/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 2007,50(16),3851-3856","journal-title":"J Med Chem"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/nn1916","volume":"10","author":"Agarwal N.","year":"2007","unstructured":"Agarwal N.; Pacher P.; Tegeder I.; Amaya F.; Constantin C.E.; Brenner G.J.; Rubino T.; Michalski C.W.; Marsicano G.; Monory K.; Mackie K.; Marian C.; Batkai S.; Parolaro D.; Fischer M.J.; Reeh P.; Kunos G.; Kress M.; Lutz B.; Woolf C.J.; Kuner R.; Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007,10(7),870-879","journal-title":"Nat Neurosci"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0024-3205(99)00289-1","volume":"65","author":"Walker J.M.","year":"1999","unstructured":"Walker J.M.; Hohmann A.G.; Martin W.J.; Strangman N.M.; Huang S.M.; Tsou K.; The neurobiology of cannabinoid analgesia. Life Sci 1999,65(6-7),665-673","journal-title":"Life Sci"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"12125","DOI":"10.1523\/JNEUROSCI.3400-08.2008","volume":"28","author":"Racz I.","year":"2008","unstructured":"Racz I.; Nadal X.; Alferink J.; Ba\u00f1os J.E.; Rehnelt J.; Mart\u00edn M.; Pintado B.; Gutierrez-Adan A.; Sanguino E.; Manzanares J.; Zimmer A.; Maldonado R.; Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 2008,28(46),12125-12135","journal-title":"J Neurosci"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"10655","DOI":"10.1073\/pnas.0610811104","volume":"104","author":"Clark A.K.","year":"2007","unstructured":"Clark A.K.; Yip P.K.; Grist J.; Gentry C.; Staniland A.A.; Marchand F.; Dehvari M.; Wotherspoon G.; Winter J.; Ullah J.; Bevan S.; Malcangio M.; Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci USA 2007,104(25),10655-10660","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"7468","DOI":"10.1038\/s41598-019-43858-4","volume":"9","author":"Nent E.","year":"2019","unstructured":"Nent E.; Nozaki C.; Schm\u00f6le A.C.; Otte D.; Zimmer A.; CB2 receptor deletion on myeloid cells enhanced mechanical allodynia in a mouse model of neuropathic pain. Sci Rep 2019,9(1),7468","journal-title":"Sci Rep"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S0028-3908(03)00195-3","volume":"45","author":"Sokal D.M.","year":"2003","unstructured":"Sokal D.M.; Elmes S.J.R.; Kendall D.A.; Chapman V.; Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology 2003,45(3),404-411","journal-title":"Neuropharmacology"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1152\/jn.00886.2003","volume":"92","author":"Nackley A.G.","year":"2004","unstructured":"Nackley A.G.; Zvonok A.M.; Makriyannis A.; Hohmann A.G.; Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 2004,92(6),3562-3574","journal-title":"J Neurophysiol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejphar.2005.10.020","volume":"527","author":"LaBuda C.J.","year":"2005","unstructured":"LaBuda C.J.; Koblish M.; Little P.J.; Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 2005,527(1-3),172-174","journal-title":"Eur J Pharmacol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1124\/jpet.103.060079","volume":"308","author":"Hohmann A.G.","year":"2004","unstructured":"Hohmann A.G.; Farthing J.N.; Zvonok A.M.; Makriyannis A.; Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 2004,308(2),446-453","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1111\/j.1460-9568.2006.04684.x","volume":"23","author":"Beltramo M.","year":"2006","unstructured":"Beltramo M.; Bernardini N.; Bertorelli R.; Campanella M.; Nicolussi E.; Fredduzzi S.; Reggiani A.; CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 2006,23(6),1530-1538","journal-title":"Eur J Neurosci"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"Pertwee R.G.","year":"2010","unstructured":"Pertwee R.G.; Howlett A.C.; Abood M.E.; Alexander S.P.; Di Marzo V.; Elphick M.R.; Greasley P.J.; Hansen H.S.; Kunos G.; Mackie K.; Mechoulam R.; Ross R.A.; International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 2010,62(4),588-631","journal-title":"Pharmacol Rev"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","volume":"152","author":"Ryberg E.","year":"2007","unstructured":"Ryberg E.; Larsson N.; Sj\u00f6gren S.; Hjorth S.; Hermansson N.O.; Leonova J.; Elebring T.; Nilsson K.; Drmota T.; Greasley P.J.; The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007,152(7),1092-1101","journal-title":"Br J Pharmacol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1242\/jcs.020958","volume":"121","author":"Waldeck-Weiermair M.","year":"2008","unstructured":"Waldeck-Weiermair M.; Zoratti C.; Osibow K.; Balenga N.; Goessnitzer E.; Waldhoer M.; Malli R.; Graier W.F.; Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 2008,121(Pt 10),1704-1717","journal-title":"J Cell Sci"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.bbrc.2007.08.078","volume":"362","author":"Oka S.","year":"2007","unstructured":"Oka S.; Nakajima K.; Yamashita A.; Kishimoto S.; Sugiura T.; Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 2007,362(4),928-934","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"29817","DOI":"10.1074\/jbc.M109.050187","volume":"284","author":"Kapur A.","year":"2009","unstructured":"Kapur A.; Zhao P.; Sharir H.; Bai Y.; Caron M.G.; Barak L.S.; Abood M.E.; Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 2009,284(43),29817-29827","journal-title":"J Biol Chem"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13041-017-0318-7","volume":"10","author":"Shi Q.X.","year":"2017","unstructured":"Shi Q.X.; Yang L.K.; Shi W.L.; Wang L.; Zhou S.M.; Guan S.Y.; Zhao M.G.; Yang Q.; The novel cannabinoid receptor GPR55 mediates anxiolytic-like effects in the medial orbital cortex of mice with acute stress. Mol Brain 2017,10(1),38","journal-title":"Mol Brain"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1385\/JMN:13:1-2:55","volume":"13","author":"Lagalwar S.","year":"1999","unstructured":"Lagalwar S.; Bordayo E.Z.; Hoffmann K.L.; Fawcett J.R.; Frey W.H.; Anandamides inhibit binding to the muscarinic acetylcholine receptor. J Mol Neurosci 1999,13(1-2),55-61","journal-title":"J Mol Neurosci"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/sj.bjp.0705577","volume":"140","author":"Savinainen J.R.","year":"2003","unstructured":"Savinainen J.R.; Saario S.M.; Niemi R.; J\u00e4rvinen T.; Laitinen J.T.; An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 2003,140(8),1451-1459","journal-title":"Br J Pharmacol"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1248\/bpb.21.224","volume":"21","author":"Kimura T.","year":"1998","unstructured":"Kimura T.; Ohta T.; Watanabe K.; Yoshimura H.; Yamamoto I.; Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol Pharm Bull 1998,21(3),224-226","journal-title":"Biol Pharm Bull"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/0006-8993(82)91016-2","volume":"235","author":"Hillard C.J.","year":"1982","unstructured":"Hillard C.J.; Bloom A.S.; delta 9-Tetrahydrocannabinol-induced changes in beta-adrenergic receptor binding in mouse cerebral cortex. Brain Res 1982,235(2),370-377","journal-title":"Brain Res"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2165\/00023210-200317030-00004","volume":"17","author":"Croxford J.L.","year":"2003","unstructured":"Croxford J.L.; Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003,17(3),179-202","journal-title":"CNS Drugs"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev.biochem.75.103004.142819","volume":"76","author":"Venkatachalam K.","year":"2007","unstructured":"Venkatachalam K.; Montell C.; TRP channels. Annu Rev Biochem 2007,76,387-417","journal-title":"Annu Rev Biochem"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pharmthera.2007.01.005","volume":"114","author":"Starowicz K.","year":"2007","unstructured":"Starowicz K.; Nigam S.; Di Marzo V.; Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007,114(1),13-33","journal-title":"Pharmacol Ther"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1054\/plef.2001.0349","volume":"66","author":"Di Marzo V.","year":"2002","unstructured":"Di Marzo V.; De Petrocellis L.; Fezza F.; Ligresti A.; Bisogno T.; Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 2002,66(2-3),377-391","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.tips.2008.10.008","volume":"30","author":"Akopian A.N.","year":"2009","unstructured":"Akopian A.N.; Ruparel N.B.; Jeske N.A.; Patwardhan A.; Hargreaves K.M.; Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol Sci 2009,30(2),79-84","journal-title":"Trends Pharmacol Sci"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3390\/cells3030914","volume":"3","author":"Ryskamp D.A.","year":"2014","unstructured":"Ryskamp D.A.; Redmon S.; Jo A.O.; Kri\u017eaj D.; TRPV1 and endocannabinoids: emerging molecular signals that modulate mammalian vision. Cells 2014,3(3),914-938","journal-title":"Cells"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-015-0743-x","volume":"17","author":"Lowin T.","year":"2015","unstructured":"Lowin T.; Straub R.H.; Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis. Arthritis Res Ther 2015,17,226","journal-title":"Arthritis Res Ther"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0014-2999(00)00396-4","volume":"404","author":"Oz M.","year":"2000","unstructured":"Oz M.; Tchugunova Y.B.; Dunn S.M.; Endogenous cannabinoid anandamide directly inhibits voltage-dependent Ca(2+) fluxes in rabbit T-tubule membranes. Eur J Pharmacol 2000,404(1-2),13-20","journal-title":"Eur J Pharmacol"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1124\/jpet.107.125336","volume":"323","author":"Oz M.","year":"2007","unstructured":"Oz M.; Yang K.H.; Dinc M.; Shippenberg T.S.; The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes. J Pharmacol Exp Ther 2007,323(2),547-554","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0006-8993(03)02808-7","volume":"978","author":"Nicholson R.A.","year":"2003","unstructured":"Nicholson R.A.; Liao C.; Zheng J.; David L.S.; Coyne L.; Errington A.C.; Singh G.; Lees G.; Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res 2003,978(1-2),194-204","journal-title":"Brain Res"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1124\/pr.58.4.5","volume":"58","author":"Michalik L.","year":"2006","unstructured":"Michalik L.; Auwerx J.; Berger J.P.; Chatterjee V.K.; Glass C.K.; Gonzalez F.J.; Grimaldi P.A.; Kadowaki T.; Lazar M.A.; O\u2019Rahilly S.; Palmer C.N.; Plutzky J.; Reddy J.K.; Spiegelman B.M.; Staels B.; Wahli W.; International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006,58(4),726-741","journal-title":"Pharmacol Rev"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejphar.2005.05.032","volume":"517","author":"Bouaboula M.","year":"2005","unstructured":"Bouaboula M.; Hilairet S.; Marchand J.; Fajas L.; Le Fur G.; Casellas P.; Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 2005,517(3),174-181","journal-title":"Eur J Pharmacol"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1084\/jem.20070828","volume":"204","author":"Ghosh M.","year":"2007","unstructured":"Ghosh M.; Wang H.; Ai Y.; Romeo E.; Luyendyk J.P.; Peters J.M.; Mackman N.; Dey S.K.; Hla T.; COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J Exp Med 2007,204(9),2053-2061","journal-title":"J Exp Med"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1124\/jpet.107.123265","volume":"322","author":"D\u2019Agostino G.","year":"2007","unstructured":"D\u2019Agostino G.; La Rana G.; Russo R.; Sasso O.; Iacono A.; Esposito E.; Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous PPAR-agonist, modulates carrageenan-Induced paw edema in mice. J Pharmacol Exp Ther 2007,322,1137-1143","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1124\/jpet.106.111385","volume":"319","author":"LoVerme J.","year":"2006","unstructured":"LoVerme J.; Russo R.; La Rana G.; Fu J.; Farthing J.; Mattace-Raso G.; Meli R.; Hohmann A.; Calignano A.; Piomelli D.; Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 2006,319(3),1051-1061","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.nurt.2008.05.003","volume":"5","author":"Landreth G.","year":"2008","unstructured":"Landreth G.; Jiang Q.; Mandrekar S.; Heneka M.; PPARgamma agonists as therapeutics for the treatment of Alzheimer\u2019s disease. Neurotherapeutics 2008,5(3),481-489","journal-title":"Neurotherapeutics"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3233\/JAD-142349","volume":"46","author":"Altamura C.","year":"2015","unstructured":"Altamura C.; Ventriglia M.; Martini M.G.; Montesano D.; Errante Y.; Piscitelli F.; Scrascia F.; Quattrocchi C.; Palazzo P.; Seccia S.; Vernieri F.; Di Marzo V.; Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer\u2019s Disease patients as a potential protective mechanism against neurodegenerative decline. J Alzheimers Dis 2015,46(2),497-506","journal-title":"J Alzheimers Dis"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1476-5381.2008.00048.x","volume":"156","author":"Pertwee R.G.","year":"2009","unstructured":"Pertwee R.G.; Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009,156(3),397-411","journal-title":"Br J Pharmacol"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179461","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/179461\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/179461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T16:06:26Z","timestamp":1608221186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179461\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":207,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,9,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x18666200217140255","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}